|
Administration
Levamlodipine: May be taken with or without food.
|
|
Special Precautions
Patient with severe aortic stenosis; severe obstructive coronary artery disease, heart failure with reduced ejection fraction, hypertrophic cardiomyopathy and outflow tract obstruction. Hepatic impairment. Children and elderly. Pregnancy and lactation. Monitoring Parameters Monitor heart rate and blood pressure.
|
|
Adverse Reactions
Significant: Worsening angina, acute MI, reflex tachycardia, symptomatic hypotension.
Cardiac disorders: Dyspnoea, palpitation.
Gastrointestinal disorders: Nausea, abdominal pain.
General disorders and administration site conditions: Fatigue, asthenia.
Hepatobiliary disorders: Jaundice.
Investigations: Increased liver enzymes.
Metabolism and nutrition disorders: Peripheral oedema.
Musculoskeletal and connective tissue disorders: Muscle cramps.
Nervous system disorders: Dizziness, extrapyramidal disorder.
Psychiatric disorders: Somnolence, insomnia.
Reproductive system and breast disorders: Sexual dysfunction, gynaecomastia.
Skin and subcutaneous tissue disorders: Rash, pruritus.
Vascular disorders: Flushing.
|
|
Drug Interactions
May increase serum concentrations with moderate and strong CYP3A4 inhibitors. May increase the serum levels of simvastatin, lovastatin, immunosuppressants (e.g. ciclosporin, tacrolimus).
|
|
CIMS Class
|
|
ATC Classification
C08CA17 - levamlodipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
|
Sign Out
